Search Results - dan+longo

2 Results

Sort By:

Transformation of Weak or Non-Immunogenic Antigens to Produce an Immune Response and Therapeutic Polypeptides for the Treatment and Prevention of Cancer

Abstract: A significant challenge in developing therapies for the treatment and prevention of cancer has been the discovery, selection, and exploitation of antigens. Researchers at the National Institute on Aging (NIA) have partially circumvented this issue in their development of novel strategies for rendering weakly or non-immunogenic, shared antigens...

Published: 4/8/2024 | Inventor(s): Bira Arya, Dan Longo, Igor Espinoza-Delgado

Keywords(s): ANTIGEN, Biragyn, CANCER VACCINE, Chemokine, National Institute on Aging, NIA

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics

Model Th1 Clone Producing IFN-gamma and IL-2

Available for licensing is the A.E7 T cell clone, a model Th1 clone described in Matis et al., J Immunol. 1983 Apr;130(4):1527-1535 [PubMed abs] and J Immunol. 1983 Sep;131(3):1049-1055 [PubMed abs]. This clone has been further utilized as a model for studying T cell clonal anergy.

Published: 7/25/2024 | Inventor(s): Ronald Schwartz, Louis Matis, Dan Longo, Toby Hecht

Keywords(s): RXXXXX

Category(s): Collaboration Sought > Licensing, Application > Research Materials